期刊
MOLECULAR THERAPY
卷 29, 期 2, 页码 540-554出版社
CELL PRESS
DOI: 10.1016/j.ymthe.2020.12.022
关键词
-
资金
- Stoke Therapeutics
Single-stranded oligonucleotides have been explored as a therapeutic modality for over 20 years, but only in the last 5 years have they become a preferred modality in precision medicine and targeted therapeutics. They have been used to treat a range of diseases from neurological to muscular to metabolic, showcasing their versatility as a robust therapeutic platform.
Single-stranded oligonucleotides have been explored as a therapeutic modality for more than 20 years. Only during the last 5 years have single-stranded oligonucleotides become a modality of choice in the fields of precision medicine and targeted therapeutics. Recently, there have been a number of development efforts involving this modality that have led to treatments for genetic diseases that were once untreatable. This review highlights key applications of single-stranded oligonucleotides that function in a sequence-dependent manner when applied to modulate precursor (pre-)mRNA splicing, gene expression, and immune pathways. These applications have been used to address diseases that range from neurological to muscular to metabolic, as well as to develop vaccines. The wide range of applications denotes the versatility of single-stranded oligonucleotides as a robust therapeutic platform. The focus of this review is centered on approved single-stranded oligonucleotide therapies and the evolution of oligonucleotide therapeutics into novel applications currently in clinical development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据